It is important for your patients to know that they should not give themselves a
CIMZIA injection unless they have been shown how by a doctor or nurse, or someone
they know has been trained to help them with their injections. You can read the
instructions below to learn the steps your patients need to follow to inject CIMZIA.
Let the medicine in the syringe come to room temperature before injection. This
will take about 30 minutes.
Hold the syringe so the needle is pointing up. Lightly tap the syringe to push any
air bubbles to the top. Push the plunger slowly to remove any bubbles. Stop pushing
the plunger once all of the air bubbles are gone. If a small drop of liquid comes
out of the needle, that is okay.
Hold the syringe with the needle facing down. Do not touch the needle with your
fingers or let it touch any surface.
Release the skin pinch, keeping the syringe in position. Pull back slowly on the
plunger. If blood enters the syringe, this means you have entered a blood vessel.
Do not inject CIMZIA. Pull the needle out and throw away the prefilled syringe and
needle in a puncture-proof container. Repeat the steps to prepare for an injection
using a new prefilled syringe. Do not use the same prefilled syringe.
If no blood appears, inject all of the medicine in the prefilled syringe under the
To avoid needle-stick injury, do not try to recap the needle. Throw away the used
prefilled syringe and needle in a special puncture-proof container. (See the section
entitled How should I throw away needles and syringes?)
Repeat steps 5 to 13 above if you are prescribed to take a second injection of CIMZIA
(total 400 mg dose).
*By disposing of the CIMZIA syringe in a UCB-provided SHARPS™ container, UCB
complies with the California Senate Bill 486 that calls for the safe collection
and proper disposal of prefilled syringes.
OXO Good Grips® and the associated
logos are trademarks of Helen of Troy Limited and are used under license.
NEXT: Safety Information
CIMZIA is indicated for the treatment of adults with moderate to severe rheumatoid
Important Safety Information
Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients
*Not valid for prescriptions that are reimbursed, in whole or part, under Medicare (including Medicare Part D), Medicaid, similar federal or state funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico) or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, Tricare, VA and DoD) for reimbursement. Patients and pharmacists are responsible for notifying insurance carriers or other third party who pays for or reimburses any part of the prescription filled using this card as may be required by the insurance carrier's terms and conditions and applicable law. The parties reserve the right to amend or end this program at any time without notice.
For more information 1-866-4-CIMZIA (1-866-424-6942)
For U.S. Healthcare Professionals
UCB, Inc. All rights reserved.
CIMZIA® and CIMplicity®
are trademarks of the UCB Group of Companies.
OXO Good Grips® and the associated logos are trademarks of Helen of Troy Limited
and are used under license.